Fig. 3

Niraparib treatment alters the proportion and function of tumor-associated lymphocytes in vivo. A Representative images of immunohistochemistry (IHC) staining for poly ADP-ribose polymerase (PARP1) in human normal ovarian tissues and ovarian cancer samples. Scale bar:100 μm. B Expression of PARP1 its relationship with clinical characteristics in ovarian cancer. C Representative images of IHC staining for programmed cell death ligand (PD-L1) and CD8 in human normal ovarian tissues and ovarian cancer samples. Scale bar:100 μm. D The correlation of CD8a and PD-L1 in GEPIA database. E-K Flow cytometry analysis of CD3⁺T cells, CD3⁺CD4⁺T cells, CD3⁺CD8⁺T cells, CD4⁺IFN-γ⁺ cells, and CD8⁺ IFN-γ⁺ cells of the Niraparib treatment patients. All experiments were repeated three times. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01